Cytek Biosciences, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 total revenue to be in the range of $188 million to $192 million, representing growth of 15% to 17% over full year 2022. This includes an expected revenue contribution from organic business to be approximately flat versus 2022 and inorganic revenue in the range of $25 million to $30 million from the Luminex flow cytometry and imaging business, which was acquired on February 28, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +2.31% | -2.70% | -36.84% |
Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.84% | 756M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023